This is just a glimpse of the insights available to CivicScience clients. Want to see the full picture? Let’s talk.
For months, CivicScience has been tracking Ozempic and GLP-1 medication usage to better understand its impact on consumer preferences. Although brand names for the drugs – such as Ozempic and Wegovy – are becoming ever-more present in the American consciousness, awareness of the term GLP-1 remains low, especially when lacking context around weight loss.
The latest data in the Ozempic and LP-1 Consumer Tracker underscores the most up-to-date information on awareness and usage, lifestyle changes, and the potential ramifications on retail, food and beverage, and other industries. Here are three key takeaways from our most recent report.
Take Our Poll: Would you ever use a weight loss drug like Ozempic?
1. Price Is a Pain Point
Currently, Americans pay substantially more for weight loss drugs than Europeans. A recent article revealed that while Ozempic costs $936 a month for Americans, those in the UK pay just $93. It likely comes as no surprise, then, that 12% of Americans indicate cost as the biggest obstacle to taking Ozempic or another GLP-1 medication. This percentage increases to 40% among those who intend to take the drug in the future. The second-biggest concern is regarding side effects.
Get the full data set in the GLP-1 Consumer Tracker.
2. Sideswiped by Side Effects
As it stands, 44% of current GLP-1 users reported moderate or severe side effects, with fatigue and low energy ranking as the most common symptoms. Given that nearly half of GLP-1 users plan to take the medication – which is considered a “forever drug”– for the long-term or indefinitely, the ongoing impact of symptoms is worth taking note.
Join the Conversation: Do you have a positive or negative view of Ozempic for weight loss?
3. Alcohol Consumption Continues to Decline
Alcohol consumption among current GLP-1 users is at a record low after months of steady decline, with 47% of GLP-1 users drinking at least one alcoholic beverage per week. With current users being frequent beer drinkers, a continued drop in alcohol consumption could impact the industry.
As Ozempic and other GLP-1 medications become increasingly present in the mind of the American consumer, the nuances around interest, usage, and impact become increasingly apparent. Stay up-to-date on in-depth insights with the monthly CivicScience Ozempic and GLP-1 Consumer Tracker. Get started with a free preview.
